Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody

Behavioural Pharmacology

Volumn 13, Issue 5-6, 2002, Pages 465-473

  McMillan, D E ^a   Hardwick, W C ^a   Li, Mi ^a   Owens, S M ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

(+) amphetamine; (+) methamphetamine; Cocaine; Drug discrimination; Monoclonal anti methamphetamine anti body; Pigeons; Rat

Indexed keywords

AMPHETAMINE; COCAINE; METHAMPHETAMINE; METHAMPHETAMINE ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISCRIMINATION LEARNING; DOSE RESPONSE; DRUG ABUSE; DRUG DISCRIMINATION; DRUG POTENCY; MALE; NONHUMAN; PIGEON; RAT;

EID: 0036747896     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200209000-00019     Document Type: Article

References (19)

1. Bazin-Redureau MI, Renard CB, Scherrmann JM (1997). Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat. J Pharm Pharmacol 49:277-281.
2. Byrnes-Blake KA, Carroll FI, Abraham P, Owens SM (2001). Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int Immunopharmacol 1:329-338.
3. Hardin JS, Wessinger WD, Proksch JW, Owens SM (1998). Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs. J Pharmacol Exp Ther 285:1113-1122.
4. Holtzman SG (2001). Differential interaction of GBR 12909, a dopamine uptake inhibitor, with cocaine and methamphetamine in rats discriminating cocaine. Psychopharmacology 155:180-186.
5. Jarbe TUC (1993). Repeated testing with drug discrimination learning: time course studies with cocaine, amphetamine, and 3-PPP. Pharmacol Biochem Behav 44:481-486.
6. Mansbach RS, Balster RL (1993). Effects of mazindol on behavior maintained or occasioned by cocaine. Drug Alcohol Depend 31:183-191.
7. McMillan DE, Hardwick WC, Li Mi (2001). Discrimination of pentobarbital doses and drug mixtures under fixed-ratio and fixed-interval reinforcement schedules. Behav Pharmacol 12: 195-208.
8. Munzar P, Goldberg SR (2000). Dopaminergic involvement in the discriminative-stimulus effects of methamphetamine in rats. Psychopharmacology 148:209-216.
9. Preston KL, Bigelow GE (1998). Opioid discrimination in humans: discriminative and subjective effects. Behav Pharmacol 9:533-543.
10. Proksch JW, Gentry WB, Owens SM (2000). Anti-phencyclidine monoclonal antibodies provide long term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J Pharmacol Exp Ther 292:831-837.
11. Riviere GJ, Byrnes KA, Gentry WB, Owens SM (1999). Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. J Pharmacol Exp Ther 291:1220-1226.
12. Riviere GJ, Gentry WB, Owens SM (2000). Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. J Pharmacol Exp Ther 292:1042-1047.
13. Schecter MD (1997). Discriminative characteristics of high and low cocaine administration: effect of other psychostimulants. Pharmacol Biochem Behav 56:457-463.
14. Schuster CR, Johanson CE (1988). Relationship between the discriminative stimulus properties and subjective effects of drugs. In: Transduction Mechanisms of Drug Stimuli. Colpaert FC, Balster RL, (editors). Berlin: Springer-Verlag, pp. 161-175.
15. Spiegelberg HL, Weigle WO (1967). The immune response to human γ-G-immunoglobulin in rabbits unresponsive to FC fragments and H chain protein. J Immunol 98:1020-1027.
16. Tidey JW, Bergman J (1998). Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs. J Pharmacol Exper Ther 285:1163-1174.
17. Valentine JL, Aronold LM, Owens SM (1994). Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats. J Pharmacol Exp Ther 269:1079-1085.
18. Valentine JL, Mayerson M, Wessinger WD, Arnold LW, Owens SM (1996). Anti-phencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. J Pharmacol Exp Ther 278:709-716.
19. Weissman A, Milne GM, Melvin LS Jr (1982). Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. J Pharmacol Exp Ther 223:516-523.